Role of pharmacogenetics and tacrolimus dosing in liver transplantation James Fung Editorial 25 October 2022 Pages: 1 - 3
Clinical application of artificial liver and blood purification: expert consensus recommendations Yu ChenTao HanSevere Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association Guidelines 02 November 2022 Pages: 4 - 17
Can living donor liver transplantation provide similar outcomes to deceased-donor liver transplantation for hepatocellular carcinoma? A systematic review and meta-analysis Beshoy Effat ElkomosMostafa AbdoAmr Abdelaal Review Article Open access 23 December 2022 Pages: 18 - 37
Hepatitis B: “Treat all” or “Treat select” Ankur JindalShiv K. Sarin Point-of-View 31 October 2022 Pages: 38 - 41
Effects of antiviral therapy and drug withdrawal on postpartum hepatitis in pregnant women with chronic HBV infection Minghui LiFangfang SunYao Xie Original Article 15 September 2022 Pages: 42 - 51
The effectiveness of combination therapy with interferon and nucleoside analogs in pediatric patients with chronic hepatitis B: a systematic review and meta-analysis Min LiQinghong LiHongfei Zhang Original Article 05 December 2022 Pages: 52 - 62
The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion Xian-Long MengJia-Cheng LuGuo-Ming Shi Original Article Open access 22 November 2022 Pages: 63 - 76
Albumin, filamin-A and cytokeratin 19 help distinguish intrahepatic cholangiocarcinoma from extrahepatic adenocarcinoma Yeon Seung ChungYoungsic JeonYoung Nyun Park Original Article 17 October 2022 Pages: 77 - 85
Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab Takeshi HatanakaSatoru KakizakiOn behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) Original Article 09 September 2022 Pages: 86 - 96
Integrated genomic analyses of hepatocellular carcinoma Ya-Sian ChangSiang-Jyun TuJan-Gowth Chang Original Article 06 December 2022 Pages: 97 - 111
Identification and development of a novel risk model based on cuproptosis-associated RNA methylation regulators for predicting prognosis and characterizing immune status in hepatocellular carcinoma Duguang LiZhaoqi ShiHui Lin Original Article 04 January 2023 Pages: 112 - 130
Low-dose continuous terlipressin infusion is effective and safer than intravenous bolus injections in reducing portal pressure and control of acute variceal bleeding Vinod AroraShakti Prasad ChoudharyShiv Kumar Sarin Original Article 21 December 2022 Pages: 131 - 138
Risk factors for portopulmonary hypertension in patients with cirrhosis: a prospective, multicenter study Masanori AtsukawaAkihito TsubotaKatsuhiko Iwakiri Original Article 07 December 2022 Pages: 139 - 149
Influence of shunt occlusion on liver volume and functions in hyperammonemic cirrhosis patients having large porto-systemic shunts: a randomized control trial Amar MukundShakti Prasad ChoudhuryShiv Kumar Sarin Original Article 12 September 2022 Pages: 150 - 158
Establishment and validation of a prediction model for the first recurrence of Budd–Chiari syndrome after endovascular treatment: a large sample size, single-center retrospective study Zhongkai WangZiwei WangHao Xu Original Article Open access 26 December 2022 Pages: 159 - 169
Maternal and perinatal outcome in pregnancies complicated with portal hypertension: a systematic review and meta-analysis Koustav PalDeepthy Melepurakkal SadanandanAnish Keepanasseril Original Article 08 July 2022 Pages: 170 - 179
Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures Zhenbin DingHong WuJian Zhou Original Article Open access 18 October 2022 Pages: 180 - 189
N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD Liang-Jie TangGang LiMing-Hua Zheng Original Article 24 September 2022 Pages: 190 - 201
Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn’s disease but not Ulcerative Colitis: a prospective cohort study Jie ChenLintao DanXue Li Original Article Open access 04 October 2022 Pages: 202 - 214
The association between visceral adipocyte hypertrophy and NAFLD in subjects with different degrees of adiposity Haixiang SunDa FangYan Bi Original Article 07 September 2022 Pages: 215 - 224
Prevalence, characteristics, and mortality outcomes of obese and nonobese MAFLD in the United States Allen D. DaoVy H. NguyenMindie H. Nguyen Original Article 29 October 2022 Pages: 225 - 236
Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion Chunmei YangGuanya GuoYing Han Original Article Open access 30 October 2022 Pages: 237 - 248
Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial Apurva PandeShvetank SharmaShiv K. Sarin Original Article 05 December 2022 Pages: 249 - 261
Impact of single-nucleotide polymorphisms on tacrolimus pharmacokinetics in liver transplant patients after switching to once-daily dosing Jangho ParkKwang-Woong LeeKyung-Suk Suh Original Article 16 August 2022 Pages: 262 - 270
Correction to: Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab Takeshi HatanakaSatoru KakizakiOn behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) Correction 16 November 2022 Pages: 271 - 273
